Back to top
more

Bristol Myers Squibb (BMY)

(Delayed Data from NYSE)

$41.48 USD

41.48
13,665,302

+0.60 (1.47%)

Updated Jun 7, 2024 04:00 PM ET

After-Market: $41.48 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..

Shaun Pruitt headshot

Should Investors Buy Bristol Myers or CVS Stock Near 52-week Lows?

by Shaun Pruitt

Investors are often on the lookout for strong companies that may be undervalued and present lucrative long-term opportunities.

Bristol Myers Squibb (BMY) Stock Moves -1.19%: What You Should Know

by Zacks Equity Research

In the latest trading session, Bristol Myers Squibb (BMY) closed at $65.72, marking a -1.19% move from the previous day.

Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks

by Zacks Equity Research

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Exelixis' (EXEL) Cabozantinib Combo Study Fails to Meet Goal

by Zacks Equity Research

Exelixis' (EXEL) combo-drug study for kidney cancer fails to meet the primary endpoint of progression-free survival (PFS).

Bristol Myers (BMY) Gets EU Nod for Anemia Drug Reblozyl

by Zacks Equity Research

Bristol Myers Squibb (BMY) gets full marketing authorization from the European Commission, for Reblozyl for anemia associated with non-transfusion-dependent beta thalassemia treatment drug in adult patients.

Mirati's (MRTX) Q4 Loss Narrows, Krazati Records First Sales

by Zacks Equity Research

Mirati Therapeutics (MRTX) reports a narrower-than-expected Q4 loss and records first sales of Krazati. Stock rises in after-hours trading.

Prothena (PRTA) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Prothena (PRTA) reports better-than-expected results for the fourth quarter. The company makes considerable pipeline progress.

Editas (EDIT) Q4 Earnings Miss Estimates, Pipeline in Focus

by Zacks Equity Research

Editas (EDIT) reports a wider loss in the fourth quarter of 2022. The strategic reprioritization, announced last month, is expected to extend the company's cash runway into 2025.

Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Sanghamitra Saha headshot

5 Least-Hurt Biotech ETFs of the Last Week

by Sanghamitra Saha

Rising rate worries have weighed on the biotech sector. However, these biotech ETFs still have lost the least in recent days.

Exelixis (EXEL), Sairopa Obtains IND Clearance for ADU-1805

by Zacks Equity Research

Exelixiss' EXEL) partner Sairopa gets FDA clearance for its IND application for the oncology drug ADU-1805, a potential best-in-class monoclonal antibody for adults with advanced solid tumors.

Biotech Stock Roundup: AMGN, GILD, BMY, REGN's Q4 Results, KPRX Up on Study Update

by Zacks Equity Research

Earnings results from Amgen (AMGN), Gilead (GILD) and others are the key highlights from the biotech sector during the past week.

Exelixis (EXEL) Q4 Earnings Top, Revenues Beat on Cabometyx

by Zacks Equity Research

Exelixis (EXEL) beats earnings and sales estimates for the fourth quarter due to increased Cabometyx sales volume.

Sweta Killa headshot

A Look at Pharma ETFs Post Q4 Earnings

by Sweta Killa

Combining the actual results with the estimates for the still-to-report companies, total earnings for the healthcare sector are expected to decline 9% on revenue growth of 4.3%.

Company News for Feb 3, 2023

by Zacks Equity Research

Companies in The news Are: META, BMY, PH, CAH.

Bristol-Myers (BMY) Q4 Earnings Top, Revlimid Generic Impact Sales

by Zacks Equity Research

Bristol-Myers' (BMY) fourth-quarter 2022 earnings beat estimates, while sales declined year over year due to generic erosion for oncology drug Revlimid.

Compared to Estimates, Bristol Myers (BMY) Q4 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Economic Data Deluge

by Zacks Equity Research

Economic Data Deluge.

Mark Vickery headshot

Goldilocks Econ Data Presides Over Pre-Market

by Mark Vickery

We haven't thrown around the term "Goldilocks" too much lately, but this morning, the shoe fits.

Bristol Myers Squibb (BMY) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Bristol Myers (BMY) delivered earnings and revenue surprises of 6.43% and 2.37%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Drug/Biotech Stocks Q4 Earnings Due on Feb 2: GILD, MRK & Others

by Zacks Equity Research

Let's look at the four biotech/pharma companies slated to release quarterly results on Feb 2.

Pfizer (PFE) Q4 Earnings Top, 2023 View Disappoints, Stock Down

by Zacks Equity Research

Pfizer (PFE) beats estimates for Q4 earnings and sales. Its 2023 financial outlook falls short of expectations. Stock down in pre-market trading.

Qiagen (QGEN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 Top Dividend Stocks to Maximize Your Retirement Income

by Zacks Equity Research

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Bristol Myers Squibb (BMY) closed at $72.45 in the latest trading session, marking a -0.74% move from the prior day.